A trial evaluating the efficacy and safety of binimetinib versus physician’s choice chemotherapy (PCC) for low-grade serous ovarian carcinomas (LGSOCs) revealed that binimetinib had activity in LGSOC across the efficacy endpoints evaluated, according to an article published in the Journal of Clinical Oncology.
The analysis included 303 patients with recurrent or persistent LGSOC who were randomised to receive either binimetinib 45 mg twice daily (n=201) or PCC (n=102). The primary endpoint was progression-free survival (PFS). Additional assessments included overall survival (OS), overall response rate (ORR), duration of response (DOR), and safety.
Median PFS was 9.1 months for binimetinib and 10.6 months for PCC, resulting in early study closure. Secondary efficacy endpoints were similar in the two groups: ORR 16% versus 13%, median DOR 8.1 months versus 6.7 months, and median OS, 25.3 versus 20.8 months for binimetinib and PCC, respectively. A post hoc analysis suggested a possible association between KRAS mutation and response to binimetinib.
The authors conclude that although this trial did not meet its primary endpoint, binimetinib did display a clinically meaningful PFS and ORR and should be considered a viable treatment option. Forthcoming biomarker analysis may help identify a subset of patients who benefit from binimetinib.